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Abstract
Dysregulation of pre-mRNA splicing machinery activity has been related to the biogenesis
of several diseases. The serine/arginine-rich protein kinase family (SRPKs) plays a critical
role in regulating pre-mRNA splicing events through the extensive phosphorylation of
splicing factors from the family of serine/arginine-rich proteins (SR proteins). Previous
investigations have described the overexpression of SRPK1 and SRPK2 in leukemia and
other cancer types, suggesting that they would be useful targets for developing novel antitu-
mor strategies. Herein, we evaluated the effect of selective pharmacological SRPK inhibi-
tion by N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)isonicotinamide (SRPIN340) on the
viability of lymphoid and myeloid leukemia cell lines. Along with significant cytotoxic activity,
the effect of treatments in regulating the phosphorylation of the SR protein family and in
altering the expression of MAP2K1, MAP2K2, VEGF and FAS genes were also assessed.
Furthermore, we found that pharmacological inhibition of SRPKs can trigger early and late
events of apoptosis. Finally, intrinsic tryptophan fluorescence emission, molecular docking
and molecular dynamics were analyzed to gain structural information on the SRPK/
SRPIN340 complex. These data suggest that SRPK pharmacological inhibition should be
considered as an alternative therapeutic strategy for fighting leukemias. Moreover, the
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Introduction
More than 90% of all human transcribed genes may undergo alternative splicing, a mechanism
that allows a considerable increase of the encoding potential of eukaryotic genomes [1]. This
process leads to the expression of different protein isoforms that may possess even antagonistic
functions, as occurs with VEGF pro- and anti-angiogenic isoforms [2,3]. Pre-mRNA splicing
flexibility plays a key role in tissue development and cell response to external stimuli, unsur-
prisingly explaining why dysregulation of these events has been related to the biogenesis of
many human diseases, including cancer [2,4].
Regulation of pre-mRNA splicing involves hundreds of auxiliary factors that control splic-
ing site selection, spliceosome assembly and splice reaction [5,6]. The serine/arginine protein
family (SR proteins) constitutes an important group of splicing factors responsible for delimi-
tating intron and exon boundaries in pre-mRNAs [5,7]. These proteins act in response to envi-
ronmental changes and are structurally characterized by an amino-terminal portion possessing
one or two RNA-binding domains (RRM) and a carboxy-terminal portion comprising a
domain rich in serine and arginine residues (RS) [8,9]. These serine residues are extensively
phosphorylated by different kinases, notably by serine/arginine-rich protein kinases (SRPKs)
[10]. This kinase family possesses a bi-lobular kinase domain separated by a divergent spacer
region that is targeted by molecular chaperones in the context of the EGFR/PI3K/Akt/SRPK
signaling pathway [10]. The signaling module EGFR/PI3K/AKT is commonly related to multi-
ple cancers and constitutes the major activation mechanism known for SRPKs to date [11–14].
Activated SRPKs, in turn, regulate SR proteins’ cellular sublocalization, splicing site selection
and interaction with additional protein factors [15,16]. Moreover, SRPKs can also activate
AKT in the cytosol through a mechanism involving the phosphatase pleckstrin homology (PH)
domain leucine-rich repeat protein phosphatase PHLPP [17].
Overexpression and dysregulation of SRPKs have been characterized as important factors in
promoting cell proliferation in many human cancers including leukemia, pancreatic, breast,
colon, lung, ovarian and melanoma [15,18–22]. Considering leukemias, SRPK1 has been found
to be overexpressed in patients with acute lymphoblastic leukemia and chronic myeloid leuke-
mia [23,24]. High levels of SRPK2 in some acute myeloid leukemia cell lines and in acute lym-
phoblastic leukemia specimens have been correlated to cell proliferation through the acinus SR
protein hyperphosphorylation and cyclin A1 expression [15]. In general, it is believed that
overexpression of SRPKs may alter the proper activity of SR factors on their primary transcript
target, favoring the expression of splicing isoforms that contribute to tumorigenic processes
[12]. Hence, the available data suggest that SRPK inhibition could control tumor cell prolifera-
tion [15,18].
Previous high throughput screening campaigns have identified the N-(2-(piperidin-1-yl)-
5-(trifluoromethyl)phenyl)isonicotinamide, also named SRPIN340, as an ATP-competitive
inhibitor that is highly selective for SRPK1 and SRPK2 [25,26]. This inhibitor has been charac-
terized as an antiviral agent against the replication of several viruses, such as HIV, Sindbis
virus, HCV and hepatitis C [25,27,28]. In addition, it presented anti-angiogenic activity in an
ocular murine angiogenesis model [29–32] and antitumor activity when locally injected into
human melanoma tumors developed in mice transplanted with human melanoma cells [22].
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Considering that SRPK dysregulation can lead to AKT hyperactivation and can additionally
generate multiple abnormal protein isoforms involved in the biogenesis and progression of sev-
eral cancers, this work describes an in vitro evaluation of the antileukemia potential of SRPK
pharmacological inhibition. In addition, structural data that might explain SRPIN340’s inhibi-
tory activity on SRPK2 are also described.
Experimental Procedures
Cell lines
The leukemia cell lines used were K562 (chronic myelogenous leukemia—CML); KG1 and
HL60 (acute myelogenous leukemia—AML); Jurkat, TALL, and Molt4 (T-cell acute lympho-
blastic leukemia–ALL-T); and RS4, 697, and Nalm6 (B-cell acute lymphoblastic leukemia–
ALL-B). K562, HL60, RS4, and 697 were kindly provided by Dr. Sheila A. Shurtleff (St. Jude
Children’s Research Hospital, Memphis, TN). The Nalm6 cell line was provided by Dr. Angelo
Cardoso (Dana-Farber Cancer Institute, Boston, MA). TALL was kindly provided by Dr. Joao
T. Barata (Instituto de Medicina Molecular, Lisboa, Portugal). The KG1, Molt4, and Jurkat
cell lines were provided by Dr. Alexandre E. Nowill (Centro Integrado de Pesquisas Oncohe-
matológicas da Infância, UNICAMP, Campinas, Brazil). Cells were cultivated in RPMI 1640
(Sigma) medium supplemented with 10% (v/v) fetal bovine serum (FBS) (LGC Biotecnologia),
100 g/mL streptomycin, and 100 units/mL penicillin at pH 7.2 and 37°C under a 5% CO2
atmosphere.
Isolation of PBMC from human blood
Peripheral blood was collected in EDTA tubes, diluted with an equal volume of Hank’s bal-
anced salt solution (HBSS) and mixed gently. All procedures were performed according to eth-
ics considerations of the Declaration of Helsinki and were approved by the ethics committee of
the Universidade Federal de Viçosa. Afterwards, samples were layered onto a cushion of Histo-
paque 1077 (Sigma) and centrifuged at room temperature for 30 min at 400 xg. Mononuclear
cells were collected from the interface, washed twice in HBSS, and centrifuged at room temper-
ature for 8 min 240 xg. These cells were resuspended in complete RPMI 1640 medium supple-
mented with 10% fetal bovine serum and 1% (v/v) phytohemagglutinin (Gibco) and counted
using a Neubauer chamber for the following experiments.
SRPK inhibitor synthesis
Compound N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)isonicotinamide (SRPIN340) was
synthesized as published previously [26].
MTT cell viability assay
Leukemic cells (5x104 cells/well) and isolated PBMCs (8x104 cells/well) were seeded in 96-
well plates. Each well contained 100 μL of complete RPMI medium and 100 μL of SRPIN340
solution at different concentrations. The compound was diluted in RPMI medium with 10%
fetal bovine serum and 0.4% DMSO (v/v). After 48 h of culture, MTT (5 mg/mL, Sigma) was
added to the wells (3 h, 37°C). The plates were centrifuged at room temperature for 30 min
500 xg, followed by the removal of the MTT solution and the addition of 100 μL/well of DMSO
(Sigma) to solubilize the formazan. Absorbance was measured at 540 nm in a microplate reader
(Sinergy HT, Biotek). Each experimental procedure was performed in triplicate.
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Flow cytometry assays
Cultured cells were seeded on a 96-well plate at a density of 105 cells/well. After treatments,
cells were labeled using an FITC Annexin V apoptosis detection kit I (BD Biosciences) accord-
ing to the manufacturer’s protocol. Subsequently, cell samples were submitted to analysis by
flow cytometry (FACS Verse, BD Bioscience). Results were analyzed by FlowJo software.
RT-PCR and RT-qPCR Analysis
mRNA was extracted from leukemic cells using Tri Reagent (Sigma) according to the manufac-
turer’s protocol. Samples were quantified by spectrophotometry (NanoDrop, Thermo Scien-
tific) and analyzed for integrity in 1% agarose gel. Afterwards, the RNA was used for first-
strand cDNA synthesis using the Super Script First-Strand kit (Invitrogen) according to the
manufacturer’s protocol. Then, the cDNA was used to amplify each fragment of interest by
PCR using the GoTaq Green Master Mix (Promega) kit, and the products were separated in
1% or 2% agarose gels. Quantitative gene expression analyses (RT-qPCR) were performed in
an ABI Prism 7500 Sequence Detector system (Applied Biosystems) using SYBR Green I dye
(SYBR Green PCRMaster Mix, Applied Biosystems). cDNAs, obtained as described above,
were used as the template for amplifications following the manufacturer's protocols. All prim-
ers used in the RT-PCR and RT-qPCR assays are listed in S1 Table.
Western Blot Analysis
Cells were counted using a Neubauer chamber and washed once in phosphate buffered saline
(PBS). Cells were lysed in PBS containing 1% (v/v) NP40, 1 mM EDTA, 150 mMNaCl, prote-
ase and phosphatase inhibitors (Sigma), and 10 mM Tris (pH 7.4) at a concentration of 2x107
cells/mL in lysis buffer. Samples were incubated on ice for 10 minutes, lysed by pipetting, and
centrifuged for 10 minutes at 15000 xg to remove insoluble cellular debris. An equal volume of
2X sample buffer containing 4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 20% (v/v) glycerol,
and 100 mM Tris (pH 6.8) was added to the supernatant. Then, the samples were heated to
70°C for 10 min. Approximately 1.5x105 cell equivalents were loaded per well of 10% Bis-Tris
SDS–polyacrylamide gel electrophoresis. Afterwards, proteins were transferred to a polyvinyli-
dene difluoride (PVDF) membrane (GE Healthcare), blocked overnight in PBS containing 5%
(w/v) skim milk powder, and then incubated for 2 h with primary antibody solutions. Specific
kinases were detected using 1:4000 dilutions of anti-SRPK1 and anti-SRPK2 (BD Biosciences).
Phosphorylated SR proteins were detected using a 1:1000 dilution of mAb1H4 (Invitrogen)
specific for a phospho-epitope common to multiple SR proteins. Each blot was re-probed with
a 1:1000 dilution of anti-actin (Sigma), used as an endogenous control in all experiments. Blots
were washed in PBS-Tween (PBS-T) and incubated for 2 h in a 1:5000 dilution of a peroxidase-
conjugated secondary antibody. Then, proteins were visualized using a Super Signal West Pico
Chemiluminescent Substrate Kit (Thermo Scientific).
Cloning, expression and purification procedures
The clone pCMV-SPORT6-SRPK2 was purchased from the Mammalian Gene Collection
(Invitrogen). This clone allowed amplification of full-length SRPK2 cDNA by PCR and sub-
cloning into the pET28a-HIS-TEV vector [33], a modified version of the bacterial expression
vector pET28a (Novagen). The following primers were used: forward primer 5'-GAGCTCA
TGTCAGTTAACTCTGAGAAGTCG-3' and reverse primer 5'-GTCGACCTAAGAATTCA
ACCAAGGATGCC-3’. Expression of SRPK2 N-terminally fused to 6xHistidine (6xHis) was
induced in Escherichia coli (BL21) by 0.25 mM isopropyl thio-β-D-galactoside (IPTG) for 2 h
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at 30°C. After harvesting, the pellets were resuspended in 20 mM phosphate, 500 mMNaCl,
and 20 mM imidazole at pH 7.4. Lysis was performed by adding 5 U of DNAse (Fermentas)
and 30 μg/mL of lysozyme (Sigma) followed by 30 min of incubation on ice and disruption by
10 cycles of sonication. Supernatants were obtained after centrifugation at 24586 xg for 15 min
at 4°C. The obtained supernatants were loaded onto a HiTrap Chelating HP column (GE
Healthcare) coupled to an AKTA FPLC (GE Healthcare) equilibrated with lysis buffer. The
6xHis-SRPK2 was eluted by a gradient of 0–500 mM. The obtained Ni2+ affinity-purified frac-
tions were dialyzed against a buffer containing 10 mM phosphate at pH 7.5. After a 2-fold dilu-
tion, samples were then loaded onto a CHT Ceramic Hidroxy Hepatite type II (Biorad) resin
ion-exchange column. Proteins were eluted by a gradient of 0–500 mM phosphate. The effi-
ciency of each purification step was verified by 10% SDS-PAGE. The following dialyses were
performed against the sample buffer: 25 mM Tris-HCl, 100 mMNaCl, 1 mM β-mercaptoetha-
nol, and 2 mM EDTA at pH 7.5.
Fluorescence Spectroscopy
Intrinsic tryptophan fluorescence emission was measured using a fluorescence spectrophotom-
eter F-4500 (Hitachi). SRPK2 emission spectra were acquired at 20°C using 1 μM of protein
dissolved in 25 mM Tris-HCl (pH 7.5) buffer, 100 mM NaCl, 1 mM EDTA and 1 mM β-mer-
captoethanol in a 1.0 x 0.2 cm quartz cuvette. Tryptophan residues were excited at 295 nm, and
the fluorescence emission was collected from 300 nm to 420 nm. SRPK2 spectra were analyzed
by means of the maximum fluorescence wavelength (λmax) and the spectral center of mass
(<λ>) following the equation<λ> = (ƩλiFi)/(ƩFi), where λi is the fluorescence wavelength
and Fi is the fluorescence intensity at a given wavelength.
SRPK2 at 1 μMwas titrated with SRPIN340 or the ATP analog adenosine 5'-(beta, gamma-
imino)triphosphate (AMPPNP). All spectra were corrected by inner filter effects due to ligand
absorption, and the dissociation constant (KD) for the SRPK2-SRPIN340 interaction was calcu-
lated as described previously [34].
Computational Analyses
Atomic charges and optimal geometry of the tridimensional structure of SRPIN340 were calcu-
lated by DFT quantum calculations at the B3LYP/6-31G level using the CHELPG method
[35]. All calculations were carried out in GAMESS software [36]. Then, quantum charges were
implemented to the topology generated by the PRODRG server [37].
All SRPK2 structures found in the Protein Data Bank (PDB; www.pdb.org) repository are
truncated forms lacking the spacer insert domain (SID), amino acids A236-R507. Structure
PDB ID 2X7G was solved based on a SRPK2 recombinant version presenting the segments
A236-P256 and A508-D510, generating a SID-like loop. Because this 2X7G crystal structure
lacks some coordinates of SID-like loop atoms, they were modeled using the Swiss Model
server. The obtained model SRPK2-SID-like loop comprising the amino acids A236-P256 and
A508-D510 was then used as a target for SRPIN340 docking. For simplification, "SRPK2-SID-
like loop structure" is herein named "SRPK2 structure". Docking assays were carried out inside
of the SRPK2 ATP binding pocket, as previously identified for SRPK1 [38]. Fifty poses of
SRPIN340 bound to SRPK2 were generated using the software Auto Dock 4.2.5.1, exploring
the conformational space of the ligand through a genetic algorithm while the target protein
was considered a rigid body [39]. Poses were ranked according to the lowest energy and best
interaction network using the Auto Dock 4 scoring function [40].
Molecular dynamics simulations were carried out on the SRPIN340/SRPK2 complexes
using the GROMACS 4.5.5 software package [41]. First, SRPK2 topology was built using the
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Gromos53a6 force field [42]. A single point charge extended (SPC/E) water model was used to
fill up a cubic water box built around previously generated SRPIN340/SPRK2 complexes.
Moreover, amounts of Na+ and Cl- corresponding to a concentration of 0.15 M were added to
the system to neutralize protein net charges and mimic the cellular environment. After a care-
ful minimization protocol, equilibration protocols were applied to ensure a proper thermody-
namic description of the system. The system was equilibrated for 4 ns using NVT assemble
(constant number of moles, volume and temperature) and NPT assemble (constant number of
moles, pressure and temperature), consecutively. Additionally, restraint forces (Fc = 1000 kcal/
mol.nm²) were used for all non-hydrogen atoms to reach a temperature stabilization of 298 K
and pressure stabilization of 1 bar. Afterwards, a non-restrained production phase of molecular
dynamics was performed using an integration step of 2 fs by the leap-frog algorithm for a tra-
jectory of 400 ns. A cut-off of 10 Å was adopted to calculate long-range interactions. Simula-
tions were performed in a cluster Silicon Graphics International (SGI Inc.).
Statistical analysis
All numeric data were derived from at least three independent experiments and are shown as
means ± standard deviation. Analyses were performed using Microsoft Excel (Microsoft Office
Software), GraphPad Prism (GraphPad Software Inc.) and ImageJ. Statistical analyses were
done by paired Student’s T tests. P<0.05 or P<0.01 was considered significant.
Results
Expression of SRPK1 and SRPK2 in leukemia cells
To expand previous findings [15] and gain further information about the relative proportion
between SRPK1 and SRPK2 expression among the leukemia cells used in this work, we evalu-
ated the expression of SRPK1 and SRPK2 in a panel of leukemia cell lineages from different ori-
gins and genetic backgrounds.
Whereas no large differences in SRPK1 protein expression among the lineages were
observed, at the protein level (Fig 1A), SRPK2 presented a distinct elevated expression in line-
ages of lymphoid origin, such as Molt4, TALL, Jurkat (ALL-T) and RS4 (ALL-B). Additionally,
Molt4, TALL, Jurkat and RS4 cells presented a higher SRPK2 protein expression compared to
SRPK1. Further RT-qPCR experiments revealed that among the nine lineages studied, only
Molt4 and Jurkat presented correlations between mRNA and protein levels, indicating that
additional layers of complexity involving the gene expression control of these kinases might
exist in these cells, which deserves additional investigation in future studies (Fig 1B). We also
used human PBMC as a control for non-transformed cells in Western blotting and RT-qPCR
experiments. However, SRPK1 and SRPK2 were barely expressed (S1 Fig) or were even unde-
tected in these assays (Fig 1A).
Taken together, these results demonstrate that the expression of SRPK1 and SRPK2 are pro-
portionally distinct among the leukemia cells analyzed. Moreover, a clear correlation between
mRNA and protein levels could not be found, reflecting the genetic diversity of these cells and
possibly their outcomes during drug treatments.
Effect of SRPK pharmacological inhibition on leukemia cell viability and
death
The emerging relevance of SRPKs as targets for pharmacological intervention has motivated
the identification of the inhibitor SRPIN340 (SR Protein Inhibitor 340) and, more recently, its
derivative SPHINX (SR Protein Inhibitor X). These compounds seem to possess equivalent
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biological properties in terms of potency, inhibition of SR protein phosphorylation, reduction
in the expression of pro-angiogenic VEGF, and suppression of choroidal neovascularization
[43]. Because SRPIN340 activity has been extensively characterized and used in different stud-
ies to date, it was chosen as a prototype for pharmacological intervention in leukemia cells
here.
The cytotoxic potential of SRPIN340 was evaluated against CML, AML, ALL-B and ALL-T
cell lineages. All evaluated cell lines were sensitive to the treatments, indicating that SRPK inhi-
bition indeed yields an overall antileukemia effect in vitro (Fig 2A). Half-maximal inhibitory
concentration values (IC50) (Table 1) were determined and revealed that, in general, myeloid
leukemias were more sensitive than lymphoid ones. In this case, the AML HL60 was the most
sensitive (IC50 of 44.7 μM) compared with ALL-T Molt4 and Jurkat (IC50 values of 92.2 μM
and 82.3 μM, respectively). Moreover, although an accurate IC50 value could not be determined
at higher compound concentrations, PBMC seemed to be less sensitive to SRPIN340 than the
leukemia lineages evaluated. This suggests that SRPK pharmacological inhibition can selec-
tively affect tumor cell survival.
Furthermore, Annexin V/PI staining assays were performed to evaluate whether the effect
of SRPIN340 treatment impacts Jurkat apoptosis. After 6 h of drug exposure, the cell popula-
tion in the initial events of apoptosis (Annexin V positive) was approximately twice as high
as the control group treated with DMSO for 12 h (values ranged from 1.6 to 4.5%) (Fig 2B).
Increasing exposure time to the compound resulted in raising the PI/Annexin V positive cells,
indicating the occurrence of later events of apoptosis (Fig 2B). Therefore, SRPIN340 can trigger
early and later events of apoptosis in leukemia cells.
Impact on SRPK cellular activity
In the following experiments, we attempted to confirm whether SRPIN340 treatment affects
cellular pathways targeted by SRPKs. As was previously reported, the expression or splicing
pattern of transcripts encoding for MAP2K1, MAP2K2, VEGF and FAS are influenced by SR
proteins or SRPK activity [19,32,44]. We observed that both MAP2K transcripts had their
expression impaired during SRPIN340 treatment (Fig 3). These effects were more pronounced
for MAP2K1, which had its expression reduced mainly at a prolonged incubation time. Addi-
tionally, we observed a reduction in the pro-angiogenic VEGF165 isoform and an increase in
the pro-apoptotic FAS isoform expression during the treatments. Although we could not detect
clear changes in splicing in leukemias, SRPIN340 changed the splicing of MAP2K1 in HeLa
cells (S2 Fig), suggesting that different cancer lineages may respond differently to SRPK
inhibition.
The SR protein phosphorylation status was also investigated using a monoclonal antibody
able to detect different phospho-SR protein epitopes [45,46]. As expected, the SR protein phos-
pho-epitope signal decreased during treatments of both the HL60 and Jurkat lineages (Fig 4).
Fig 1. Analysis of SRPK1 and SRPK2 expression in leukemia cell lines. The expression of SRPK1 and SRPK2 were analyzed by (A) Western blotting
and (B) RT-qPCR assays in different leukemia cell lines derived from chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), T-cell
acute lymphoblastic leukemia (ALL-T), and B-cell acute lymphoblastic leukemia (ALL-B). (A) The histogram (below) represents the ratio of the band
intensities of SRPK1 and SRPK2 normalized to the actin signal for each lineage. Densitometry analysis of the band intensity was performed using ImageJ
software. Error bars represent means ± standard deviation from triplicate experiments. Because SRPK1 or SRPK2 signals in the PBMC samples could not
be detected during the WB assays, even when higher amounts of material were used (data not shown), they were not considered for the densitometry
analysis. Although we found that actin expression varied between leukemia cells and our PBMC samples (S1 Fig), actin was detected here to qualitatively
control the presence of protein material. (B) Expression of SRPK1 and SRPK2 transcripts by relative quantification. Amplification of beta-2-microglobulin
mRNA (B2M) was used as an endogenous control. B2M was equally expressed among all of the leukemia lineages evaluated (S1 Fig and data not shown).
SRPK1 and SRPK2mRNA quantification in PBMC are discussed in S1 Fig. All primers used are detailed in S1 Table.
doi:10.1371/journal.pone.0134882.g001
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Fig 2. The effect of SRPIN340 treatment on leukemia cell viability and death.Different leukemia cell lines (A) were treated with increasing concentrations
(0–100 μM) of SRPIN340 for 48 h. Cell viability was determined using the MTT assay. We considered the viability of 100% of the cells in the control treatment
(vehicle). The percentage of inhibition was calculated relative to cells treated with the vehicle. The values are expressed as the means ± standard deviation of
three independent experiments. To assess cell death (B), Jurkat cells were treated with 25 μM of SRPIN340 for 6 or 12 h. Cells treated with the vehicle were
used as controls. Subsequently, the cell death was evaluated using annexin V-FITC (V) and PI (P) labels. One representative experiment of three is shown.
doi:10.1371/journal.pone.0134882.g002
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Overall, these results confirm that the observed decrease in leukemia cell viability upon
SRPIN340 treatment is related to an effect on pathways targeted by SRPK activity.
Insights on SRPIN340-SRPK complexes
Once we observed the pharmacological effect of SRPIN340 in leukemia cells, we sought to
investigate possible molecular interactions underlying its binding to SRPKs. While high-resolu-
tion crystallographic structures of the complex SRPIN340/SRPKs have not been solved to date,
computational approaches were used to infer possible binding sites into SRPK structures
Table 1. Half-maximal inhibitory concentration (IC50) values for SRPIN340 treatments. Different leuke-
mia cell lines and peripheral blood mononuclear cells (PBMC) were treated with increasing concentrations
(0–200 μM) of SRPIN340 for 48 h. Cell viability was determined using the MTT assay. The values are
expressed as the means ± standard deviation of three independent experiments.
Cell line SRPIN340 IC50 [μM]
K562 (CML) 52.0 ± 0.6
HL60 (AML) 44.7 ± 2.4
Nalm6 (ALL-B) 66.6 ± 2.7
697 (ALL-B) 59.2 ± 0.6
Molt4 (ALL-T) 92.2 ± 15.2
Jurkat (ALL-T) 82.3 ± 1.2
PBMC >100*
* The precise IC50 value could not be determined due to the low solubility of SRPIN340 at higher
concentrations.
doi:10.1371/journal.pone.0134882.t001
Fig 3. Effect of SRPIN340 treatment on MAP2K1, MAP2K2, VEGF and FAS expression in leukemia
cells. cDNAs were derived from HL60, Jurkat, Molt4 and Nalm6 cells treated with SRPIN340 (100 μM) for
different amounts of time (0, 9 and 18 h). One representative experiment of three is shown. (*) represent
possible isoforms as previously described [19].
doi:10.1371/journal.pone.0134882.g003
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Fig 4. Effect of SRPIN340 treatment on SR protein phosphorylation.Western blotting analysis after
treatment with SRPIN340 (100 μM) or negative control (vehicle) for 9 or 18 h. SR protein phosphorylation was
detected using mAb1H4, which recognizes phosphorylated serine-arginine epitopes common to multiple SR
factors. The blot was re-probed with actin and used as an endogenous control. Graphics (below) represent
the percentage of the SR proteins’ band intensity normalized to the actin signal for each HL60 and Jurkat
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currently available in PDB. A comparison of amino acid sequences revealed that both kinases
are highly similar in their kinase domains [47] (S3 Fig), explaining why SRPIN340 can inhibit
both SRPK1 and SRPK2 [25]. Considering this structural similarity, the position of the ATP
analog, previously co-crystallized with SRPK1 [38], allowed the prediction of its binding site
into SRPK2 (Fig 5A), the paralog chosen to be studied herein, because its mechanisms in leuke-
mia tumorigenesis have been previously well determined [15].
Because SRPIN340 behaves as an ATP competitive inhibitor [25], docking assays were car-
ried out inside the ATP binding pocket. To take into account protein flexibility and eventual
induced fit effects, SRPIN340/SRPK2 complexes corresponding to the best two poses obtained
by docking procedures, namely "pose A" and "pose B", were selected and used as inputs for
molecular dynamics simulations. RMSD calculations demonstrated that both systems reached
stability after 200 ns of simulation (data not shown). In both complexes, the SRPIN340 mole-
cules displayed stable conformations inside the SRPK2 catalytic pocket after 200 ns, maintain-
ing the same network interactions throughout the additional 200 ns. The space occupied by
SRPIN340 on pose A and B throughout simulation is shown as a blue and green area, respec-
tively (Fig 5A).
Interestingly, the ATP analog docked into ATP binding site (orange sticks) clearly shows
higher superposition to the blue region occupied by SRPIN340 during the molecular dynamics
of "pose A", which then seems to better explain the mechanism of competitive inhibition. In
this sense, SRPIN340 at "pose A" is additionally stabilized by T-shaped and sandwich pi-stack-
ing interactions with W89 during the last 200 ns (Fig 5B). The simulations also show residues
L87, W89, V95, A108, F166, L169, Y228, A529 and P247 acting together to form a network of
hydrophobic interactions with SRPIN340. These contacts on the SRPK2/SRPIN340 complex
were measured throughout the trajectory in the last 200 ns (Table 2). The most prominent bid-
ing groups, with low distance standard deviations, were a benzene ring, CF3 and a pyridine
ring, either in pose A or B.
Furthermore, a solvent accessible surface area (SASA) analysis revealed more exposure to
polar solvents of tryptophan amino acid residues in structures of "pose A" by approximately
100 Å2 (Fig 5C). This finding might have interesting implications if considered together with
the following intrinsic tryptophan fluorescence analysis confirmation (see below).
Together, these data can yield important information for the rational design of novel deriva-
tives with increased potency and pharmacological potential.
Intrinsic tryptophan fluorescence studies
To further understand the structural aspects of SRPK inhibition by SRPIN340, fluorescence
spectroscopy experiments using tryptophan residues as probes were carried out. The SRPK2
fluorescence spectrum at a λmax of 340 ± 1 nm and a<λ> of 347.1 ± 0.6 nm, indicates that, on
average, the SRPK2W residues are partially exposed to the polar solvent (Fig 6A). For a con-
trol, the effect of DMSO (vehicle) on the tertiary structure was also evaluated. Concentrations
up to 5% of DMSO did not affect the overall SRPK2W emission spectrum, assuring that all
observed effects are due to the presence of SRPIN340 in solution (Fig 6A).
The titration of SRPK2 with SRPIN340 resulted in a clear intrinsic fluorescence suppression
(Fig 6B), as well as in a slight redshift in the λmax and<λ> equal to 342 ± 1.0 nm and 351 ±
0.6 nm, respectively, at 15 μM SRPIN340 (Fig 6B). These results indicate an increase in W resi-
dues exposed to the solvent, suggesting that SRPK2 undergoes conformational changes in the
negative control. Densitometry analysis was performed using ImageJ software. Error bars represent the
means ± standard deviation from triplicate experiments. T tests, *P < 0.05, **P < 0.01.
doi:10.1371/journal.pone.0134882.g004
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Fig 5. Molecular Dynamic Analysis. (A) Occupied space of SRPIN340 during simulations from poses A (blue) and B (green). Average protein structures
are shown superposed in light blue for simulation A and in light green for simulation B. The ATP analogue ANP (shown in orange sticks) occupies the same
region as SRPIN340 during both simulations. (B) Snapshot from pose A (upper) and pose B (bottom) simulations highlighting the possible SRPIN340
(orange sticks) interaction network. (C) Solvent accessible surface area (SASA) for tryptophan residues in the presence of the ligand, blue and green for
poses A and B, respectively. The pose A simulation shows a signal increase at 175 ns, indicating a major exposure of residues to the polar solvent from this
point of simulation. This is in agreement with the fluorescence spectroscopy analysis shown in Fig 6.
doi:10.1371/journal.pone.0134882.g005
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presence of SRPIN340 (see also Fig 5C). The titration data additionally allowed the calculation
of the dissociation constant (KD) for the SRPK2/SRPIN340 interaction equal to 1.6 ± 0.3 μM
(Fig 6C). Furthermore, tryptophan fluorescence analysis upon ATP analogue addition revealed
no significant effects on the SRPK2 structure, even at higher ligand concentrations (Fig 6D).
These data suggest that, compared to ATP, SRPIN340 may undergo different binding modes
or access a different interaction network at the SRPK ATP binding pocket, but still act as its
inhibitor, which agrees with the computational analyses performed (Fig 5).
Discussion
Dysregulation of SR protein phosphorylation by SRPKs has been shown to play a key role in
cancer [12]. In leukemia cells, SRPK2 overexpression leads to hyperphosphorylation of the
splicing factor acinus, which in turn is responsible for increasing the transcription level of
cyclin A1 and affecting cell proliferation [15]. SRPK1 and SRPK2 have also been observed to be
overexpressed in various other human cancers, including pancreatic, breast, colon, lung and
ovarian [18–20,48]. SRPK-altered expression impacts the overall pre-mRNA normal splicing
and gene expression program, allowing cancer cells to increase their proliferation, invasiveness,
angiogenic potential and apoptosis escape [15,49]. Moreover, high SRPK levels have also been
co-related to tumor grade and resistance to chemotherapy [18,19,48]. Thus, much accumulated
data points to the fact that SRPKs are functionally relevant for tumor cells, revealing that they
can serve as a target for pharmacological intervention.
In previous immunoblotting analyses, high levels of SRPK2 have been found in leukemic
bone marrows samples (n = 5), but SRPK2 is undetectable in normal bone marrow counter-
parts [15]. To find additional information on SRPK expression in leukemia, we analyzed the
protein and mRNA levels of SRPK1 and SRPK2 in different leukemia cell lineages herein
Table 2. Average distances of SRPIN340 groups and SRPK2 binding site amino acid side-chains. Dis-
tances from the SRPIN340 groups and the amino acid side-chains’ centers of mass were measured through-
out both simulations. Standard deviation values were considered good for SD < 0.5 Å, medium for 0.5 Å <
SD < 1.0 Å and long for SD > 1.0 Å.
Pose A
Distance Average (Å) Standard Deviation (Å)
A108: Benzenic ring 5.28 0.39
L87: CF3 4.80 0.45
W89: Pyridine ring 4.78 0.48
A108: Piperidine ring 4.18 0.53
F166: Piperidine ring 5.81 0.80
L87: Benzenic ring 5.66 0.57
V95: Benzenic ring 6.00 0.62
A529: Piperidine ring 6.68 1.28
A529: Pyridine ring 7.12 1.54
P247: CF3 8.38 3.93
Pose B
Distance Average (Å) Standard Deviation (Å)
L87: Benzenic ring 4.72 0.45
V95: Piperidine ring 5.13 0.38
Y228: N-cyclohexane 6.21 0.69
L169: CF3 5.90 1.63
Y228: O-amide 5.26 1.77
doi:10.1371/journal.pone.0134882.t002
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(Fig 1). Both kinases were found with elevated expression in all cell lines evaluated, but none of
them could be detected at significant levels in the PBMCs by Western blotting or RT-qPCR
(Fig 1 and S1 Fig). These data are in agreement with previous studies reporting that SRPK1
and SRPK2 are overexpressed in primary bone marrow leukemia samples in comparison with
healthy ones [15,23,24].
Additionally, considering protein levels, the proportions of SRPK1 and SRPK2 were differ-
ent among the lineages studied, reflecting the existence of different regulatory mechanisms
operating in these cells to yield altered SRPK1 and SRPK2 expression. It is important to notice
that the SRPK2 protein expression was higher than that of SRPK1 in the lineages ALL-T
(Molt4, TALL and Jurkat) and ALL-B (RS4) (Fig 1A). This difference is intriguing and certainly
would impact therapies based on compounds presenting specificity for SRPK1 or SRPK2.
Therefore, these gene expression data, along with others previously reported [15,23,24], rein-
force the fact that the therapeutic potential of SRPK inhibition should be considered against
hematological malignances.
Based on these accumulated SRPK1 and SRPK2 gene expression data, we aimed to investi-
gate the cytotoxic effect of the SRPK inhibitor SRPIN340 on leukemia cells [25,26]. This
Fig 6. SRPK2/SRPIN340 interaction studied by fluorescence spectroscopy. (A) DMSO titration (0–5% v/v) of SRPK2 spectra showing no significant
changes in the local tertiary structure of the W residues. (B) Fluorescence spectra of the SRPK2 titration with increasing concentrations (0–15 μM) of
SRPIN340. (C) Data analysis of the spectra shown in (B) and SPRK2/SRPIN340 dissociation constant (KD) determination. The KD found for this interaction
was 1.6 ± 0.3 μM. (D) SRPK2 (1 μM) fluorescence spectra upon addition of several concentrations of ATP analogue.
doi:10.1371/journal.pone.0134882.g006
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substance has been previously shown to be selective for SRPK1 and SRPK2 because no relevant
inhibitory activity was observed against a panel of more than 140 kinases, including Cdc-like
kinase family members (Clks) that are also involved in SR protein phosphorylation and regula-
tion [25]. Although SRPIN340 was first described as an antiviral agent [25,27,28], its pharma-
cological activity has also been evaluated in other studies. For instance, it was able to prevent
neovascularization in a rodent model of choroidal retinopathy of prematurity [30]. In addition,
this compound exhibits antiangiogenic and anti-melanoma effects both in vitro and in vivo
[22]. In the present investigation, SRPIN340 was shown to reduce cell viability of myeloid and
lymphoid leukemias in vitro (Fig 2 and Table 1). This effect seemed to be selective, as lower
cytotoxicity was observed in PBMC treatments. This finding is in agreement with the low
apparent toxic effect observed when SRPIN340 was evaluated in in vivo studies [25,26].
Furthermore, Annexin V staining cell death assays showed that SRPIN340 cytotoxicity
involves the triggering of early and late apoptosis, corroborating previous studies that have
shown increased tumor cell sensitivity to cisplatin and gemcitabine during SRPK knockdown
experiments [15,18]. Interestingly, the Jurkat and Molt4 lineages seemed more resistant to
SRPIN340 treatment (Table 1). This finding might be due to the comparatively higher SRPK2
protein expression in these cells (Fig 1A). It is well known that SRPIN340 has a higher inhibi-
tory activity over SRPK1 compared to SRPK2 [50], implying that this compound would be less
effective against tumor cells with higher SRPK2 expression.
Because the SR protein phosphorylation status was reduced during treatments, the
SRPIN340 effect on leukemia cells seemed to be associated with SRPK inhibition (Fig 4). It is
also interesting to notice that the effect on SR protein phosphorylation in HL60 seemed to be
more effective than in Jurkat, which might be again explained by the differences in the propor-
tion of SRPK1/SRPK2 in these cells.
Additionally, we observed in RT-PCR assays that SRPIN340 treatment impaired the
expression of MAP2K1 and MAP2K2, both responsible for activating the MAPK3 and
MAPK1 pathways [19]. The treatments led to a reduced expression principally of MAP2K1, in
which decreased levels were also accompanied by a decreased expression of possible smaller
variants (Fig 3). In contrast, when we treated HeLa cells with SRPIN340, a smaller splicing var-
iant of MAP2K1 was expressed, indicating that the compound can favor spliced isoforms with
less tumorigenic potential (S2 Fig). However, the same effect on splicing could not be observed
for MAP2K2, VEGF or FAS in leukemia or HeLa cells, suggesting that different tumor lineages
may respond differently to SRPK inhibition. When similar analyses were performed with
breast, colonic, and pancreatic carcinoma lineages, the SRPK1 knockdown impacted the
expression of MAP2K2 instead of MAP2K1 [19], providing additional evidence for this differ-
ent response according to each cell line. Regardless, the impaired gene expression observed in
our assays indicates that cell survival pathways involving MAPK3, MAPK1 and Akt are
affected by SRPIN340 treatment.
SRPIN340 reduced the expression of pro-angiogenic isoform VEGF165 in all leukemia cell
lines evaluated, mainly after 18 h of treatment. At the same time, pro-apoptotic FAS expression
was induced (Fig 3). These data give more support, as previously described, that SRPK inhibi-
tion may be related to triggering apoptosis [19,51]. Additionally, recent studies have shown
that SRPK1 targeting is a reasonable strategy for cancer treatment due to the inhibition of
angiogenesis [22,32]. Thus, the key role played by SRPKs in regulating cellular death or prolif-
eration offers novel opportunities to develop antileukemia therapies.
The in vivo anti-melanoma effect of SRPIN340 has been recently demonstrated [22]. This
effect was shown to be mediated by antiangiogenic activity and required dairy SRPIN340
administrations to the tumor locally due to the low pharmacological capacity of SRPIN340.
This finding indicates that novel compounds with increased drug-like properties should be
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searched for in future studies. In recent years, a number of anticancer agents that reached clini-
cal use were developed through ‘target-based’ approaches, mostly involving the knowledge of
structural aspects of ligand-target interactions [52]. Following this rationale, the possible inter-
action contacts between SRPIN340 and SRPK2 evaluated herein create a path to develop novel
inhibitors with higher affinities and increased drug-like characteristics [22].
Molecular dynamics simulation analyses revealed a high stability of the SRPK2/SRPIN340
complex, reinforcing the robustness of the docking assays that were performed (Fig 5). W
exposure to the polar solvent across the trajectories analyzed was readily detected and indicates
that the ligand binding induced conformational changes in the kinase structure. According to
this finding, further intrinsic W fluorescence assays revealed that SRPIN340 caused a slight
redshift and induced W fluorescence suppression in the SRPK2 spectrum (Fig 6). These obser-
vations may be explained by the exposure of W residues to the polar solvent or even by the for-
mation of pi-stacking interactions observed between SRPIN340 and W89 in the molecular
dynamics simulation of pose A, confirming that overall conformational changes occur upon
SRPIN340 binding (Fig 5B and 5C).
SRPIN340 titration in the fluorescence assays also allowed estimation of the KD value for
the SRPK2/SRPIN340 complex at 1.6 ± 0.3 μM. Previous studies with the yeast SRPK homo-
logue Sky1p revealed KD values for the ATP analogue and ATP equal to 650 μM and 2000 μM,
respectively [53]. Considering these values, SRPIN340 binding seems to occur with higher
affinity than would be expected for adenine nucleotides. Although comparisons between these
data should be made carefully, the huge differences in these values might indicate that the
ATP-competitive SRPIN340 indeed accesses different interacting groups at the ATP binding
pocket because they were obtained using different experimental methodologies.
The possible binding modes analyzed here presented different interactions made by
SRPIN340. They were classified by their distances’ standard deviations (Table 2) as good
(SD< 0.5 Å), medium (0.5 Å< SD< 1.0 Å) and long (SD> 1 Å). For pose A, contacts on the
benzenic ring (A108), CF3 (P247) and the pyridine ring (W89) groups were more stable, cor-
roborating the hypothesis of hydrophobic forces playing a critical role in SRPIN340 binding.
In addition, interactions A108 and F166 with the piperidine ring and interactions L87 and
V95 with the benzenic ring created a suitable environment for SRPIN340 accommodation.
Together, these interactions led to a binding mode of a type I kinase inhibitor. However, these
contacts can be further improved, along with the ones with higher deviations, to design more
suitable SRPK inhibitors. Although all structural analyses were performed considering SRPK2,
interpretations may also be applied to SRPK1, considering the high similarity in their kinase
domains [10,47] (S3 Fig). Additionally, SPHINX appears to be equivalent to SRPIN340 in
terms of chemical properties and in vitro and in vivo activities [43,54], and the structural infor-
mation obtained here may therefore complement the biological and biochemical data already
available in the literature for both compounds. Considered together, all of this information will
certainly sustain efforts to pursue next-generation SRPK inhibitors.
In conclusion, SRPKs were found overexpressed in myeloid and lymphoid leukemia. The
SRPK inhibitor SRPIN340 presented a selective cytotoxic effect against leukemia cell lines. This
effect was accompanied by the triggering of apoptosis, and it was due to intracellular SRPK
activity impairment. Finally, the structural insights obtained should favor the design of SRPK
inhibitors with increased potency and drug-like properties.
Supporting Information
S1 Fig. RT-qPCR analysis comparing SRPK2 mRNA expression in Molt4 and Nalm6 leuke-
mia cells in relation to PBMC.mRNA expression analysis (A) shows that SRPK2 has higher
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expression in Molt4 and Nalm6 compared with non-transformed PBMC. Because all genes
amplified to be used as endogenous controls strongly varied between the PBMC and leukemia
cells (see graphs B-D), the data were normalized using the unit of mass of the starting material
[55,56]. For this analysis, equal amounts of total RNA and cDNAs were carefully determined
spectrophotometrically, allowing us to plot the relative expression values as 2ΔCt, where PBMC
was used as a calibrator (ΔCt = Ct(PBMC)—Ct(SRPK)). The same approach was attempted with
SRPK1, but its expression could not be precisely compared with the leukemia cells (see graph
E) because it was barely detected in the PBMC samples. Nevertheless, this indicates that
SRPK1 has very low expression in PBMC, which is in good agreement with our WB assays
(Fig 1A) and with previous RT-qPCR reports [23,24]. The primers used in these experiments
are detailed in S1 Table.
(TIF)
S2 Fig. Effect of SRPIN340 treatment on MAP2K1, MAP2K2, VEGF and FAS expression
in HeLa cells. RT-PCR was performed using primers specific for MAP2K1, MAP2K2,
VEGF, and FAS genes, and cDNA were derived from HeLa cells after 18 h of treatment with
SRPIN340 (100 μM). Cells treated with the vehicle DMSO were used as a control. One repre-
sentative experiment of three is shown. () MAP2K1 splicing variant as previously described
[19].
(TIF)
S3 Fig. Superposition of SRPK1 and SRPK2 crystallographic structures. SRPK1 (PDB ID
1WAK, grey) and SRPK2 (PDB ID 2X7G, blue) structures were aligned attesting their high
similarity.
(TIF)
S1 Table. List of primers.
(PDF)
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